US/UK/Canada

Share

Pick a time period -
Tags ( Active)

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease

Stockholm, Sweden, July 13, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer’s disease. The US launch is planned for late August 2026.Leqembi Iqlik is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance. It is administered via an autoinjector,

New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer’s disease

Stockholm, Sweden, July 12, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care

New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

Stockholm, Sweden, June 30, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer’s Association International Conference (AAIC) in London, July 12–15, including data on its subcutaneous formulation, long-term use across diverse patient groups, maintenance dosing, and at-home administration.BioArctic will also participate in the Plenary Session “Prevalence of Alzheimer’s Disease Pathology in the Community,” taking place on 14 July (11:00am to 12:15pm BST). In a presentation called “

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology

Stockholm, Sweden, June 22, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. As part of the agreement, BioArctic will receive USD 30 million in upfront payment.In addition to the upfront payment, BioArctic will be eligible to receive additional milestone payments of up to USD 770 million. BioArctic will also be

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028.As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten

Bulletin from the Annual General Meeting in BioArctic AB (publ)

Stockholm, 28 May 2026. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made.Adoption of the income statement and the balance sheet: allocation of result and determination of the record date for the dividend The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the submitted accounting documents and resolved, in accordance with the board of directors’ proposal, that a dividend of SEK 2 per share shall be paid, with 1 June 2026

BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

Stockholm, Sweden, May 25, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai’s simulation, Leqembi sales will reach around JPY 300 billion (approximately SEK 17.6 billion) for the company’s fiscal year (FY) 2028, which ends in March 2029.Eisai’s presentation can be found on https://www.eisai.com/ir/library/presentations/index.html   ---   This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse

Interim Report for the period January – March 2026

Strong financial performance with commercial milestone reached Events during the first quarter 2026 · Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment · Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks · The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China · New long‑term and real‑world data for Leqembi, presented at the AD/PD™ conference in

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027)

Stockholm, Sweden, May 15, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor

Invitation to presentation of BioArctic’s first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET

Stockholm, Sweden, May 13, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s first quarter report for January – March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET.In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session. If you wish to participate via the webcast, please use the link below, where you will be able to

Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.

Stockholm, Sweden, May 8, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi® Iqlik™, as a starting dose for the treatment of early Alzheimer’s disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.As part of the ongoing review process, the agency requested additional information and has

Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026

Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the first quarter 2026, in conjunction with their partner Biogen’s first quarter report. In total, sales of JPY 26.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 161 million, which is an increase of approximately 68 percent compared to the royalty recorded by BioArctic for the first quarter 2025.Eisai’s results for their fourth quarter and full year FY2025 (April 2025 - March 2026)

Leqembi® annual sales exceed EUR 500 million – second sales milestone achieved

Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the global sales of Leqembi surpassed EUR 500 million in Eisai’s fiscal year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 million to BioArctic.Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease. Eisai is responsible for

Notice of Annual General Meeting 2026 in BioArctic AB (publ)

The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday 28 May 2026For more information on the content of the proposals, please see the complete notice to the Annual General Meeting below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar), and in Svenska Dagbladet and on the company’s website within the next few days. NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL) The shareholders in BioArctic AB (publ), corp.reg.no. 556601-2679 (“BioArctic”) are hereby

BioArctic publishes the Annual Report and Sustainability Report for 2025

Stockholm, April 21, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company’s website. The company’s Sustainability Report and Corporate Governance Report are integrated with the Annual Report.“In 2025 BioArctic entered a new phase. Behind us, we left an era that, for just over 20 years, shaped the company we are today. 2025 was a fantastic year for BioArctic, with a breakthrough drug against Alzheimer’s disease on the global market, a broad and growing pipeline, several license agreements and a

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

Stockholm March 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 28, 2026.The Nomination Committee proposes that the board shall consist of eight members, without deputies.   The Nomination Committee proposes that Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist and Mikael Smedeby be re-

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

Stockholm, Sweden, March 23, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab.Eisai presented new real‑world findings from an analysis of long‑term treatment persistence among early Alzheimer’s disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Stockholm, Sweden, March 11, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, and online. In addition, BioArctic will have an oral presentation on lecanemab and a poster presentation relating to exidavnemab at the conference.Eisai will present lecanemab data focused on real-world efficacy and safety, as well as four-year data from the Clarity

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

Stockholm, February 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 78,000 stock options of series 2019/2028.As of February 27, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,719,485 shares, of which 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A

Interim Report for the period October – December 2025

A transformative year with record financial results Events during the fourth quarter 2025 · Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US · Leqembi was approved in Brazil and Canada · Leqembi was approved for IV maintenance treatment in the United Kingdom · Eisai submitted application for subcutaneous initiation treatment with Leqembi in Japan · New Leqembi data presented at CTAD 2025 suggested potential to delay disease progression by up to 8.3 years with continuous

Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET

Stockholm, Sweden, February 11, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s fourth quarter report for October – December 2025 on Wednesday, February 18, 2026, at 08:00 a.m. CET.In conjunction with the report, BioArctic invites investors, analysts, and media to a presentation on February 18, at 09:30 a.m. CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the fourth quarter report, followed by a Q&A session.   If you wish to participate via webcast, please use the link below. You will be

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Stockholm, Sweden, February 9, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer’s disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI), has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026.The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research,

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Stockholm, Sweden, February 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen’s fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.The strong appreciation of the Swedish krona during 2025 has had a significant impact

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media